Last edition
News about "Lupin receives EIR from U.S. FDA"
Lupin's Pithampur Unit-1 facility receives EIR from U.S. FDA
Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1, India facility. The inspection for the facility was conducted by the U.S. FDA between February 3, 2020 and February 11, 2020
Lupin Receives EIR From U.S. FDA | 30/04/2020 | By Darshana | 431
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members